Login to Your Account

Novartis canakinumab cardiovascular outcomes data provoke mixed feelings

By Cormac Sheridan
Staff Writer

Monday, August 28, 2017

DUBLIN – The numbers for the Cantos phase III cardiovascular outcomes trial of Novartis AG’s IL-beta1 inhibitor, canakinumab, are in. The data are scientifically compelling – but whether they’re good enough to alter clinical practice remains an open question.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription